Salto-Tellez M - Search Results

1

The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer.

Boyle DP, McArt DG, Irwin G, Wilhelm-Benartzi CS, Lioe TF, Sebastian E, McQuaid S, Hamilton PW, James JA, Mullan PB, Catherwood MA, Harkin DP, Salto-Tellez M. Boyle DP, et al. Histopathology. 2014 Sep;65(3):340-52. doi: 10.1111/his.12398. Epub 2014 Apr 16. Histopathology. 2014. PMID: 24612173

2

Lack of RUNX3 inactivation in columnar cell lesions of breast.

Subramaniam MM, Chan JY, Omar MF, Ito K, Ito Y, Yeoh KG, Salto-Tellez M, Putti TC. Subramaniam MM, et al. Histopathology. 2010 Oct;57(4):555-63. doi: 10.1111/j.1365-2559.2010.03675.x. Histopathology. 2010. PMID: 20955380

3

Inactivation of Rb in stromal fibroblasts promotes epithelial cell invasion.

Pickard A, Cichon AC, Barry A, Kieran D, Patel D, Hamilton P, Salto-Tellez M, James J, McCance DJ. Pickard A, et al. EMBO J. 2012 May 29;31(14):3092-103. doi: 10.1038/emboj.2012.153. EMBO J. 2012. PMID: 22643222 Free PMC article.

4

A morpho-molecular prognostic model for hepatocellular carcinoma.

Srivastava S, Wong KF, Ong CW, Huak CY, Yeoh KG, Teh M, Luk JM, Salto-Tellez M. Srivastava S, et al. Br J Cancer. 2012 Jul 10;107(2):334-9. doi: 10.1038/bjc.2012.230. Epub 2012 Jun 19. Br J Cancer. 2012. PMID: 22713659 Free PMC article.

5

RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status.

Omar MF, Ito K, Nga ME, Soo R, Peh BK, Ismail TM, Thakkar B, Soong R, Ito Y, Salto-Tellez M. Omar MF, et al. Pathol Oncol Res. 2012 Oct;18(4):783-92. doi: 10.1007/s12253-011-9485-5. Epub 2012 Jun 24. Pathol Oncol Res. 2012. PMID: 22729835 Free article.

6

Molecular diagnostics and the training of future tissue- and cell-based pathologists.

Catherwood MA, Schmitt F, Salto-Tellez M. Catherwood MA, et al. Cytopathology. 2012 Oct;23(5):283-5. doi: 10.1111/cyt.12015. Cytopathology. 2012. PMID: 22985226 No abstract available.

7

Immunohistochemistry in the era of personalised medicine.

McCourt CM, Boyle D, James J, Salto-Tellez M. McCourt CM, et al. J Clin Pathol. 2013 Jan;66(1):58-61. doi: 10.1136/jclinpath-2012-201140. Epub 2012 Sep 21. J Clin Pathol. 2013. PMID: 23002284

8

Molecular mapping the presence of druggable targets in preinvasive and precursor breast lesions: a comprehensive review of biomarkers related to therapeutic interventions.

Boyle DP, Mullan P, Salto-Tellez M. Boyle DP, et al. Biochim Biophys Acta. 2013 Apr;1835(2):230-42. doi: 10.1016/j.bbcan.2013.01.004. Epub 2013 Feb 9. Biochim Biophys Acta. 2013. PMID: 23403165 Review.

9

Guidelines and considerations for conducting experiments using tissue microarrays.

Ilyas M, Grabsch H, Ellis IO, Womack C, Brown R, Berney D, Fennell D, Salto-Tellez M, Jenkins M, Landberg G, Byers R, Treanor D, Harrison D, Green AR, Ball G, Hamilton P; National Cancer Research Institute (UK) Biomarker and Imaging Clinical Studies Group. Ilyas M, et al. Histopathology. 2013 May;62(6):827-39. doi: 10.1111/his.12118. Epub 2013 Apr 12. Histopathology. 2013. PMID: 23672312 Review.

10

Molecular and clinicopathological markers of prognosis in breast cancer.

Boyle DP, McCourt CM, Matchett KB, Salto-Tellez M. Boyle DP, et al. Expert Rev Mol Diagn. 2013 Jun;13(5):481-98. doi: 10.1586/erm.13.29. Expert Rev Mol Diagn. 2013. PMID: 23782255

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

328 results

Search Page

Filters